Nuhey News

We talk about the MARKET

The Global Anti-obesity Drugs Market to show 17.0% CAGR from 2022-28

Anti-obesity drugs are pharmacological agents that reduce or control weight. These drugs alter one of the fundamental processes of the human body, weight regulation, by altering either appetite, or absorption of calories. The main treatment modalities for overweight and obese individuals remain dieting and physical exercise.

Due to the COVID-19 pandemic, the global Anti-obesity Drugs market size is estimated to be worth US$ 1824.1 million in 2021 and is forecast to a readjusted size of US$ 5569.5 million by 2028 with a CAGR of 17.0% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Anti-obesity Drugs market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Anti-obesity Drugs landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

The report analysts forecast the Global Anti-obesity Drugs market to grow at a CAGR of 41.45 percent over the period 2013-2022.

This report focuses on Anti-obesity Drugs volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Anti-obesity Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.

Request for a free sample or purchase this report at: https://www.themarketreports.com/report/global-anti-obesity-drugs-market-research-report

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

  • Peripherally Acting Anti-obesity Drugs
  • Centrally Acting Anti-obesity Drugs

Segment by Application

  • Kids
  • Adults

By Company

  • Merck
  • Novo Nordisk
  • Pfizer
  • Arena Pharmaceuticals
  • Roche
  • GlaxoSmithKline
  • Orexigen Therapeutics
  • Vivus
  • Amylin
  • Alizyme
  • Boehringer Ingelheim
  • Eisai

Production by Region

  • North America
  • Europe
  • China

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

 

Contact Details:

Mr. Shirish Gupta

Sales Manager

The Market Reports | Industry and Market Reports at its Best

Call: +1-631-407-1315 / +91-750-729-1479

Email: sales@themarketreports.com